Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
57 studies found for:    IL2RA
Show Display Options
Rank Status Study
1 Completed
Has Results
Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
Condition: End Stage Renal Disease
Interventions: Drug: Rabbit Antithymocyte globulin;   Drug: Daclizumab
2 Suspended Preemptive Therapy of GVHD
Condition: Graft-vs-host Disease
Intervention: Drug: rabbit antithymocyte globulin
3 Completed A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Daclizumab
4 Completed Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
Condition: Renal Transplantation
5 Recruiting Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Genetic: Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
6 Completed
Has Results
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Conditions: Graft vs Host Disease;   Myelodysplastic Syndromes;   Leukemia;   Leukemia, Myeloid;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Lymphocytic;   Lymphoma;   Lymphoma, Mantle-cell;   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: RFT5-SMPT-dgA;   Drug: Isolex system
7 Unknown  Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation
Conditions: Kidney Transplantation;   Kidney Diseases;   Kidney Failure
Interventions: Drug: Alemtuzumab;   Drug: Daclizumab
8 Completed Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
Conditions: Ulcerative Colitis;   Gastrointestinal Disease;   Inflammatory Bowel Disease
Intervention: Drug: Daclizumab
9 Completed
Has Results
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
Condition: Kidney Transplantation
Interventions: Biological: DT;   Drug: Daclizumab;   Biological: KLH
10 Active, not recruiting Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
Condition: Kidney Transplantation
Interventions: Drug: Advagraf;   Biological: Simulect;   Drug: Cellcept;   Drug: Corticosteroids;   Drug: Ramipril;   Drug: Irbesartan
11 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
12 Completed
Has Results
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
Condition: Renal Transplantation
Interventions: Drug: Everolimus (RAD001);   Drug: Tacrolimus;   Drug: Basiliximab;   Drug: Corticosteroids
13 Completed Zenapax to Treat Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Zenapax
14 Completed Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay
Condition: Renal Transplant Recipients
Intervention: Other: Cylex ImmuKnow Assay
15 Completed
Has Results
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
Condition: Kidney Transplantation
Interventions: Drug: CP-690,550;   Drug: tacrolimus
16 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
17 Completed Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
Conditions: Leukemia, T-Cell;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: Yttrium-90 radiolabeled anti-Tac antibody
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
19 Recruiting Biomarkers for Acute Graft-versus-host Disease
Condition: Acute GVH Disease
Intervention: Other: no intervention
20 Withdrawn Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
Interventions: Biological: IL-2 secreting and hCL4OL-expressing autologous B-CLL cells;   Biological: IL-2;   Biological: CD40L;   Drug: ONTAK;   Biological: immunotoxin dose

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.